Evidence map›Paper›PMID 27699052›Full record

ArticleOxford medical case reports2016

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab.

M P M Graham-Brown, R Aljayyousi, R J Baines, J O Burton, N J Brunskill, P Furness, P Topham

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxford medical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M P M Graham-BrownJohn Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, UK.
R AljayyousiJohn Walls Renal Unit , University Hospitals of Leicester NHS Trust , Leicester , UK.
R J BainesJohn Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
J O BurtonJohn Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
N J BrunskillJohn Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
P FurnessDepartment of Histopathology , University Hospitals of Leicester NHS Trust , Leicester , UK.
P TophamJohn Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
University Hospitals of Leicester NHS Trust · GBUniversity of Leicester · GB

Funding

Department of Health CS-2013-13-014
6 · The paper itself

Abstract

We report the case of a 40-year-old female transplant patient with undiagnosed ANCA-associated vasculitis (AAV) and renal allograft dysfunction who achieved disease remission with restoration of transplant function following induction therapy with rituximab. There are currently no trial data looking at the use of rituximab for induction of remission of renal transplant patients with AAV. Although recurrence of AAV following renal transplantation is rare, such patients have invariably had multiple previous exposures to induction and maintenance immunosuppressive regimens, often limiting treatment options post-transplantation. In this case, rituximab was well tolerated with no side effects, and was successful in salvaging transplant function. Optimal treatment regimens for relapsed AAV in the transplant population are not known, and clinical trials are needed to evaluate the efficacy and safety of rituximab at inducing and maintaining disease remission in relapsed AAV following transplantation.

Indexed as

ANCARenalRituximabTransplantation

Identifiers

PMID27699052
PMCPMC5045541
OpenAlexW2527561605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.